FDA Approves the Immunotherapy Keytruda for Head and Neck Cancer
August 10th 2016The immunotherapy pembrolizumab (Keytruda) has been granted an accelerated approval from the FDA for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progresses after platinum-based chemotherapy.
Michael A. Postow Discusses Nurses' Role in Treating Patients Receiving Immunotherapies
April 22nd 2016Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses nurses’ roles in treating patients receiving immunotherapy, especially combination checkpoint blockades, which are typically associated with higher risks of adverse events.